This article was originally published in The Tan Sheet
Executive SummaryOTC asthma inhaler returns to store shelves in full supply, Wyeth Consumer Healthcare announces July 25. Madison, N.J.-based firm attributed previous shortage to "difficulties in procuring key components for the Primatene Mist inhaler, coupled with a product recall by another company that has no relation to Wyeth," or Primatene Mist. Wyeth emphasizes break in stock was not related to safety or efficacy of Primatene product, and is offering $1.00-off coupons on the inhaler's 1Web site and via cash register receipts to customers who were inconvenienced during the shortage...
You may also be interested in...
Nanobiotix’s CEO outlines to Scrip how the biotech plans to develop and expand its lead asset into multiple cancer indications, and create a blockbuster.
Two late-stage trials of Austedo have missed their endpoints in the neurological disorder, meaning Teva will miss out on an additional revenue stream from the VMAT2 inhibitor.
Sandoz US president Carol Lynch talked to Scrip about its changing US portfolio, which will emphasize biosimilars, as the Novartis unit is poised to divest most of its US generics portfolio to Aurobindo.